Red Cell Special Interest Group
Red Cell Defects
Day: Wednesday | Time: 10:30 - 12:00
Session Coordinators:
Lesley Bruce & Vanja Crew
Speakers:
The diagnosis and management of primary autoimmune haemolytic anaemia.
Anita Hill, Department of Haematology, St James' Institute of Oncology, Leeds
Presentation Unavailable
CRISPR/Cas9 editing of the major alpha-globin regulatory element as a curative strategy for beta-thalassaemia.
Mohsin Badat, Weatherall Institute of Molecular Medicine, Oxford
Presentation Unavailable
AG-348, a first in class pyruvate kinase activator: effects on anaemia and haemolysis in patients with pyruvate kinase deficiency.
Mark Layton, Department of Haematology, Imperial College London.
Intended Audience:
Biomedical Scientists and trainees working in hospital transfusion departments, UK Blood Services, and associated services; Research scientists involved in basic research work; Clinicians who prescribe blood components in haematology, surgery, intensive care, obstetrics and trauma settings; Transfusion practitioners; Anyone in the wider scientific community who is interested in the red cell research carried out in the UK.
Learning Objectives:
1) Familiarisation with the diagnosis and management of primary autoimmune haemolytic anaemia
2) Learning about gene editing as a curative strategy for beta-thalassaemia
3) Learning about the biochemical background to pyruvate kinase deficiency
Brief Description:
This year's Red Cell SIG session 'Red Cell Defects' aims to present novel research which will enable participants to learn about red cell defects that may cause haemolytic anaemia, membrane disorders such as hereditary spherocytosis, hereditary elliptocytosis, hereditary ovalocytosis or hereditary stomatocytosis, defects in red cell enzymes and/or haemoglobinopathies.
Session Tags:
